Home / 2020 / October / 16

Daily Archives: October 16, 2020

Trip.com partners with Etihad Airways Etihad Guest

Trip.com enters partnership with Etihad Airways

The Trip.com X Etihad Airways partnership will offer Etihad Guest members the opportunity to maximize rewards when booking accommodation through Trip.com.

SINGAPORE, Oct. 16, 2020 (GLOBE NEWSWIRE) — Trip.com, a leading international online travel service provider with over 1.4 million properties in more than 200 countries and regions, has entered into a partnership with Etihad Airways’ frequent flyer programme, Etihad Guest. This partnership will offer Etihad Guest members the opportunity to maximize rewards when booking accommodation through Trip.com.

Etihad Guest members will now be rewarded with 3 Etihad Guest Miles for every 1 USD (or currency equivalent) when they book their stay with Trip.com at www.trip.com/w/etihadguest and have access to top deals on more than 1.4 million hotels in over 200 countries and regions, including luxury hotels and resorts, business and airport hotels, and unique lodgings.

Understanding that flexibility during these times is important, Trip.com provides customers special discounts or free cancellation guarantees on advance reservations.

“As travelers around the world look towards their next trips, we are delighted to be partnering with Etihad Guest to maximize benefits for travelers from the Middle East and around the globe,” said Trip.com Group Chief Marketing Officer Bo Sun.

Yasser Al Yousuf, Vice President Commercial Partnerships, Etihad Aviation Group, said: “As global travel restrictions are eased, many of our guests are excited to travel again, and our partnership with Trip.com will further reward them, wherever their travel may take them.”

This partnership is part of Trip.com’s PointsPLUS, the easy way for partner airline frequent flyer members to earn reward miles or points when booking hotels.

To take advantage of this offer and start earning Etihad Guest Miles with Trip.com, Etihad Guest members must book a hotel stay via our the dedicated landing page at www.trip.com/w/etihadguestThe Etihad Guest points will be credited to your account within 12 weeks after the completion of stay and Etihad Guest Miles will not expire, as long as one eligible transaction is made within an 18-month period.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5a795d99-a694-4943-bf0a-7a77d66143f7

Trip.com Rep Details
For further information, please contact
Trip.com PR
Tel: (+86) 21 3406 4880 ext 196455


Align Technology Announces Commercial Availability of Previously Announced ClinCheck™ Pro 6.0 and ClinCheck “In-Face” Visualization for Invisalign Treatment

  • ClinCheck software moves digital treatment planning to the cloud for access anywhere, on any device
  • Powerful new tool aids digital treatment planning and helps patients visualize personalized treatment outcomes using their photos and 3D models

SAN JOSE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) today announced commercial availability of its previously announced proprietary ClinCheck treatment planning software which will be featured at the Align APAC Virtual Symposium on October 16, a fully digital event to showcase digital treatment techniques and feature practitioners from across the Asia Pacific region. ClinCheck software provides doctors with a 3D model of planned tooth movements throughout Invisalign treatment. ClinCheck Pro 6.0 moves Invisalign digital treatment planning to the cloud, making its robust ClinCheck treatment planning tools and features available to doctors anytime, anywhere, on any laptop, personal computer, or tablet. The release includes the new ClinCheck “In-Face” Visualization tool, an enhanced doctor-facing digital clinical tool that combines a photo of the patient’s face with their 3D Invisalign treatment plan, creating a personalized view of how their new smile could look.

ClinCheck “In-Face” Visualization is designed to help doctors with their digital treatment planning and to increase patient understanding of the benefits provided by Invisalign treatment through enhanced visualizations of their personalized treatment outcome. The ClinCheck “In-Face” Visualization workflow combines three components of Align’s digital treatment platform: Invisalign Photo Uploader for patient photos, the iTero intraoral scanner to capture data needed for the 3D model of the patient’s dentition, and ClinCheck Pro 6.0.

In addition to ClinCheck “In-Face” Visualization, ClinCheck Pro 6.0 offers users a treatment planning solution that provides doctors with a more intuitive design and an enhanced user experience. This includes improvements to allow doctor modifications through 3D controls and new education features such as dynamic tool tips and product tour. Finally, the cloud-based solution allows doctors to treatment plan with flexibility across devices and ensures that they have the latest version of the software without the need for additional downloads.

About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 8 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Align Technology
Madelyn Homick
(408) 470-1180

Zeno Group
Sarah Johnson
(828) 551-4201

DEFINE PCI study one-year data show potential of treating residual ischemia to improve clinical outcomes for coronary stent patients

October 15, 2020

New data suggest that PCI guided by iFR co-registered on the angiogram can improve outcomes and reduce angina for patients more effectively than treatment guided by angiography alone

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the one-year results of the DEFINE PCI [1] study at the Cardiology Research Foundation’s TCT Connect 2020 virtual conference. The DEFINE PCI study assessed the level of residual ischemia, or reduced blood flow to the heart muscle, found in patients after a percutaneous coronary intervention (PCI), an image-guided, minimally invasive treatment to open coronary artery blockages. The assessment was carried out using a blinded instant wave-Free Ratio (iFR) pullback measurement, a physiologic guidance technology unique to Philips.

The exciting promise of this data is that by using iFR co-registration physicians can identify precise locations causing ischemia, plan stent length and even place a virtual stent to predict physiologic improvement before the intervention is performed. The blinded acute data of DEFINE PCI revealed that 24% of patients with angiographically successful PCI still had residual ischemia. In approximately 82% of these patients, the residual ischemia was the result of a focal, potentially treatable lesion. The data suggests patients could have benefited from planning tools like iFR co-registration to find potentially treatable lesions that are often not identified by angiography alone.

The DEFINE PCI one-year data release shows that patients whose baseline ischemia was more effectively treated (post-PCI iFR ≥0.95) had improved outcomes and less recurrent angina (chest pain) at one year. The one-year data showed an optimal post-PCI iFR of ≥0.95 was associated with improved event-free survival. In fact, patients with a post-PCI iFR of ≥0.95 had 68% fewer clinical events than patients with less than optimal post-PCI iFR values (1.8% vs 5.7%, p=0.04).

“In DEFINE PCI we noted that if all lesions causing focal ischemia had been treated up-front, the rate of significant ischemia could theoretically be reduced from 24% to 5%,” said Allen Jeremias MD, principal investigator of the DEFINE PCI study. “Now with the one-year data, we find that patients with more complete resolution of ischemia do better clinically. To some that may not be a surprising finding, but we are conducting the science because, today, most interventionalists are only using physiology as a “who-to-treat” tool. Beyond who we should treat, tools like iFR can guide “how” and “where” to treat within a vessel and then confirm results after stent placement. It’s difficult to know which lesions will produce a significant physiological gradient and which won’t. If you don’t measure, really there’s no way of telling.”

“The goal is to get patients as close to normal, physiologically, as possible,” said Manesh Patel, MD, co-author of the DEFINE PCI study. “We’ve known this for a while, but we haven’t had the mature technology to deliver on this. We now have technology such as iFR co-registration to determine the risk-benefit of revascularization as well as when, how, and where we should treat – and that should lead to better outcomes for patients.”

The DEFINE PCI one-year data release follows the 500 patients who participated in the DEFINE PCI study announced last year at the American College of Cardiology (ACC) annual conference. The initial study results showed that 1 in 4 patients treated with standard of care PCI left the cath lab with residual ischemia (iFR < 0.90) [1].

“The one-year data from DEFINE PCI are the latest evidence that iFR contributes to reduced costs, enhanced patient experience and improved outcomes for PCI procedures [2, 3, 4],” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “With the recent introduction of OmniWire, the world’s first solid core pressure guide wire for coronary artery interventional procedures, as well as the next generation of our Azurion platform, we are advancing image-guided therapy with innovative, procedure-focused solutions.”

DEFINE GPS: evaluating whether iFR co-registration guidance improves patient outcomes in a large, prospective, randomized trial
In February, Philips announced DEFINE GPS, a randomized, controlled prospective trial which represents the next step in the DEFINE series of physiology studies. DEFINE GPS will assess the clinical effectiveness of iFR co-registration guidance to minimize post-PCI ischemia in patients. The study, which will include up to 3,000 participants at approximately 100 sites globally, will help determine whether a physiology-based PCI approach results in superior patient outcomes compared to standard angioplasty. Enrolment is expected to begin in Q1 2021.

The DEFINE PCI and DEFINE GPS studies are sponsored by Philips with the Cardiovascular Research Foundation overseeing core lab and clinical event committee activities.

[1] Jeremias A et al. The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.
[2] Davies JE, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
[3] Gotberg M, et al. iFR Swedeheart Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
[4] Manesh R. Patel. Cost-effectiveness of iFR compared with FFR to guide coronary revascularization decision-making-Analysis from DEFINE FLAIR. The American College of Cardiology (ACC) annual meeting in Orlando, Florida, March 10–12, 2018.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com
Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


NetJets Announces Official Worldwide Sustainability Program

The World’s Largest Private Aviation Company Commits to Carbon Offsetting Measures and Sustainable Fuel Purchase

Columbus, OH, Oct. 15, 2020 (GLOBE NEWSWIRE) — COLUMBUS, OHIO (October 15, 2020) – NetJets today launches its expanded Global Sustainability Program, a commitment to reducing the environmental footprint of the brand and its Owners. As the leader in private aviation with more than 750 aircraft worldwide, NetJets’ position in the market comes with the responsibility to drive awareness and action for important issues industry-wide. As such, the brand is developing a multi-tiered program to address sustainability and continuing to examine all aspects of its business with environmental impact in mind.

NetJets’ Global Sustainability Program focuses on:

By nature of its fractional ownership model, NetJets facilitates a sharing economy that eliminates the need to reposition flights to a home base and makes full-time ownership of an aircraft unnecessary, ultimately leading to more efficiencies and less surplus time in the sky.

“As the largest and most experienced company in the private aviation space worldwide, NetJets’ promise of exceptional safety and service to Owners and employees must extend to the larger global community we impact as well,” said Brad Ferrell, Executive Vice President of Administrative Services. “Our Sustainable Aviation Fuel purchase is crucial for the continued availability of the product in the market, and we’re excited to help create that opportunity, as well as to announce the next phase of our Global Sustainability Program. There remains more to be done in the sustainable aviation space, and we look forward to being on the cutting-edge of those innovations and evolving this program in our ongoing efforts to address sustainability in the air, on the ground and with our team members.”

In order to remain accountable, NetJets will track a number of metrics, including percentage decrease in carbon emissions and miles offset to carbon neutral, to share in bi-annual updates with Owners, employees and the larger aviation community. A subsidiary of Berkshire Hathaway, NetJets’ Global Sustainability Program aligns with the holding company’s commitment to the U.N. Sustainable Development Goals. To follow NetJets’ sustainability progress, visit https://www.netjets.com/en-us/sustainability.

About NetJets

NetJets Inc., a Berkshire Hathaway company, is the worldwide leader in private aviation. More than 50 years ago, we launched the world’s first private jet charter and management company. We went on to pioneer shared aircraft ownership—offering the advantages of owning a private jet, without the responsibilities. Today, we continue to innovate from cockpit and cabin to safety and accessibility. As the owner and operator of the world’s largest and most diverse private jet fleet, NetJets hires only the most experienced and accomplished pilots and safety is our first and highest priority. Our full range of aviation options help individuals and businesses do more and miss less via the NetJets®, Executive Jet Management®, and Marquis Jet Card® service brands in North America and Europe. For more information about the world’s most reliable and trusted aviation company, visit netjets.com.

NetJets PR Team